Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
CONTEXT: Lisdexamfetamine is a pro-drug stimulant that requires the enzymatic hydrolysis of lysine from dexamphetamine for pharmacologic effects. There is limited information comparing non-therapeutic lisdexamfetamine and dextroamphetamine exposures. OBJECTIVE: The objective was to compare lisdexamfetamine exposures with dextroamphetamine/amphetamine extended release and dextroamphetamine/amphetamine immediate release. METHODS: A retrospective observational case series of single-substance exposures to lisdexamfetamine, dextroamphetamine/amphetamine extended release, or dextroamphetamine/amphetamine immediate release reported to the National Poison Data System from 2007 to 2012 was performed. Data were analyzed for demographics, reason, clinical effects, management site, and outcomes. RESULTS: There were 23,553 exposures: lisdexamfetamine (7,113), dextroamphetamine/amphetamine extended release (6,245), and dextroamphetamine/amphetamine immediate release (10,195). The most frequent clinical effects observed for lisdexamfetamine, dextroamphetamine/amphetamine extended release, and dextroamphetamine/amphetamine immediate release were agitation (19.8%, 21.7%, and 25.1%, respectively) and tachycardia (19.2%, 22.8%, and 23.9%, respectively). The reason was most often exploratory (93.4%) in children < 6 years and therapeutic error (65.6%) in children aged 6-12 years. In adolescents and adults most common reasons were suicide attempts (28.4%) followed by abuse (19.5%) and therapeutic errors (18.8%). Overall, 61.6% of cases were managed in a health care facility, with the majority treated in the emergency department only. The majority of cases (76.0%) experienced no or minor effects. More serious outcomes (moderate/major/death) occurred in 21.2% of lisdexamfetamine, 24.7% of dextroamphetamine/amphetamine extended release, and 25.5% of dextroamphetamine/amphetamine immediate release. There were 4 deaths (1 dextroamphetamine/amphetamine extended release and 3 dextroamphetamine/amphetamine immediate release). In patients aged 6 years and more, abuse/misuse was more frequently reported for dextroamphetamine/amphetamine immediate release (32.5%) and dextroamphetamine/amphetamine extended release (23.0%) than that for lisdexamfetamine (13.5%). The odds of abuse/misuse was 2.3 (95% confidence interval [CI]: 2.0-2.4) times higher for dextroamphetamine/amphetamine immediate release than that for lisdexamfetamine and dextroamphetamine/amphetamine extended release combined; the odds of dextroamphetamine/amphetamine extended release abuse/misuse was 1.9 (95% CI: 1.7-2.2) times higher than lisdexamfetamine. In 2011, the number of lisdexamfetamine abuse/misuse cases exceeded dextroamphetamine/amphetamine extended release by approximately 26% and plateaued in 2012, but was significantly lower (∼75%) than dextroamphetamine/amphetamine immediate release. CONCLUSIONS: Toxic effects were similar for all three drugs. Although the majority of cases were treated at health care facilities, the majority of patients experienced no effects or minor toxicity. Serious outcomes occurred in approximately 21% of lisdexamfetamine and 25% of dextroamphetamine/amphetamine extended release and dextroamphetamine/amphetamine immediate release. Lisdexamfetamine may have less abuse potential, especially compared with the immediate-release dextroamphetamine/amphetamine formulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Solanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677
Findling, R. L., Childress, A. C., Cutler, A. J., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Squires, L. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.01.007 · Cited by 120
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093841 · Cited by 100
A Systematic Review of the Safety of Lisdexamfetamine Dimesylate
Coghill, D. R., Caballero, B., Sorooshian, S., & Civil, R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0166-2 · Cited by 89
Findling, R. L., Ginsberg, L. D., Jain, R., & Gao, J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0165 · Cited by 47
Lisdexamfetamine Dimesylate: A New Therapeutic Option for Attention-Deficit Hyperactivity Disorder
Steer, C., Froelich, J., Soutullo, C. A., Johnson, M., & Shaw, M. (2012) · CNS Drugs · doi:10.2165/11634340-000000000-00000 · Cited by 30
Poison Centers Detect an Unexpectedly Frequent Number of Adverse Drug Reactions to Lisdexamfetamine
Spiller, H. A., Griffith, J. R., Anderson, D. L., Weber, J. A., & Aleguas, A. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l240 · Cited by 17
Research works printed but not linked: 16
- 10.1016/j.ajem.2008.07.026 · doi:10.1016/j.ajem.2008.07.026
- 10.3109/15563650.2013.863906 · DOI · Paper page
- 10.1097/01.pra.0000445245.46424.25 · DOI
- Bloom B, 2012, Vital Health Stat, 10, 1
- 10.1007/s40263-013-0084-8 · DOI
- 10.1111/j.1742-7843.2007.00093.x · DOI
- Chundru PG, 2010, Clin Toxicol, 48, 654
- 10.4037/ajcc2012768 · DOI
- Meggs WJ, 2010, Clin Toxicol, 48, 248
- 10.3109/15563650.2014.906213 · DOI
- 10.1016/j.scitotenv.2013.02.020 · DOI
- Cassidy TA, J Atten Disord
- 10.1111/j.1521-0391.2011.00147.x · DOI
- Krishnan SM, 2008, Open-Label, single-centre, Phase I study in healthy adult volunteers. Clin Drug Invest, 28, 745
- 10.1080/15563650701233370 · DOI
- 10.1007/s10916-009-9263-z · DOI
Cited by
Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016
Piper, B. J., Ogden, C. L., Simoyan, O. M., Chung, D. Y., Caggiano, J. F., Nichols, S. D., & McCall, K. L. (2018) · PLOS ONE · doi:10.1371/journal.pone.0206100 · Cited by 170
Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy
Ermer, J. C., Pennick, M., & Frick, G. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-015-0354-y · Cited by 67
Dolder, P. C., Strajhar, P., Vizeli, P., Odermatt, A., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4849-0 · Cited by 34
Pediatric ADHD medication exposures reported to US poison control centers
King, S. A., Casavant, M. J., Spiller, H. A., Hodges, N. L., Chounthirath, T., & Smith, G. A. (2018) · Pediatrics · doi:10.1542/peds.2017-3872 · Cited by 30
Strajhar, P., Vizeli, P., Patt, M., Dolder, P. C., Kratschmar, D. V., Liechti, M. E., & Odermatt, A. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.10.016 · Cited by 17
“In 84 the US, there was also an increase in lisdexamfetamine misuse cases reported to poison 85 centers between 2007 and 2012, resulting in more cases associated with lisdexamfetamine 86 than extended-release D-amphetamine [18].”
Metadata
- Authors
- Kaland, M. E., & Klein-Schwartz, W.
- Venue
- Clinical Toxicology
- Publisher
- Informa UK Limited
- Published
- 2015-04-02
- Volume
- 53
- Issue
- 5
- Pages
- 477-485
- ISSN
- 0009-9309 (ISSN-L)
- 1556-3650
- 1556-9519
- OpenAlex
- W2064128739
- Cited by
- 39
- References
- 7
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers. https://app.cochat.ai/papers/10.3109/15563650.2015.1027903
- The paper
- Kaland, M. E., & Klein-Schwartz, W. (2015). Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers. Clinical Toxicology. https://doi.org/10.3109/15563650.2015.1027903
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.